Zasocitinib more effective than deucravacitinib in phase 3 psoriasis trial
Zasocitinib outperformed deucravacitinib in a head-to-head phase three trial for moderate to severe plaque psoriasis across multiple efficacy measures. In 16 weeks, 36.5% of 301 patients on zasocitinib achieved complete skin clearance, compared with 13.9% of 303 patients on deucravacitinib. Safety profiles were similar with mostly mild or moderate adverse events and low discontinuation rates.
Where this came from. One outlet reported this. We read it, then wrote the sixty words above.